AOD9604: Published Research

Introduction

AOD9604 (Tyr-hGH177–191) is a synthetic hexadecapeptide fragment of human growth hormone that has been the subject of peer-reviewed research across multiple experimental paradigms, including in vitro biochemical studies, chronic rodent model investigations, large-animal safety pharmacology studies, and six human clinical trials spanning Phase I through Phase IIb. A consolidated human safety analysis published in 2013 reported a tolerability profile indistinguishable from placebo across all six trials — an unusually complete safety characterization for a research peptide of this class [1]. This article summarizes the published literature by methodology type and describes the principal findings attributed to each study type.

Methodology Types

The published research on AOD9604 spans four broad methodological categories:

In vitro tissue preparations. Early studies used isolated rat adipose tissue and adipocyte preparations to characterize the biochemical activity of hGH C-terminal fragments on lipogenic enzyme systems.

Chronic rodent model studies. Multiple studies employed genetically obese mouse models (C57BL/6J ob/ob mice) and Zucker fatty rats to assess in vivo metabolic effects and mechanism-of-action hypotheses.

Large-animal and safety pharmacology studies. Nonclinical toxicology studies in rats and cynomolgus monkeys evaluated chronic safety. Pharmacokinetic studies in pigs assessed oral and intravenous disposition of the peptide.

Human clinical trials. Six randomized, double-blind, placebo-controlled trials were conducted, including two intravenous pilot studies, two oral dosing pilot studies, and two oral Phase IIb efficacy and safety studies enrolling approximately 300 and 536 participants, respectively [1].

Summary of Studies

In Vitro Biochemical Studies (1993–2000)

A 1993 publication by Wu and Ng reported that a synthetic peptide corresponding to residues 177–191 of hGH exhibited antilipogenic activity in isolated rat adipose tissue equivalent to that of intact hGH, as measured by inhibition of lipid synthesis from radiolabeled acetate [2]. The authors also reported no statistically significant lipolytic effect (measured as glycerol release) in this in vitro system, proposing that the C-terminal domain harbors antilipogenic activity that may operate through a distinct mechanism from the lipolytic activity under these experimental conditions [2].

A 2000 study by Ng et al. examined a structurally related fragment, AOD9401, in isolated Zucker fatty rat adipose tissue and reported stimulation of hormone-sensitive lipase and inhibition of acetyl-CoA carboxylase — effects consistent with both pro-lipolytic and antilipogenic activities at the cellular enzyme level [3]. The authors also reported reduced adipocyte cell diameter in chronically treated animals compared with controls, adding morphological evidence to the biochemical observations [3].

Chronic Rodent Model Studies (1994–2001)

A 1994 study by Natera, Jiang, and Ng reported that chronic treatment of C57BL/6J (ob/ob) obese mice with synthetic hGH 177–191 was associated with reduced cumulative body weight gain and adipose tissue mass relative to saline-treated controls over the treatment period [4]. Inhibition of lipogenesis in adipose tissue was reported in the treated animals, consistent with the in vitro antilipogenic findings [4].

A 2000 study published in the American Journal of Physiology — Endocrinology and Metabolism examined oral administration of AOD9401 in ob/ob mice and reported statistically lower body weight gain in treated animals from day 16 onward compared to controls, along with reduced lipogenic activity and increased lipolytic activity in adipose tissue, and acute increases in energy expenditure and fat oxidation as measured by indirect calorimetry [5]. The oral route of administration in a rodent model was a notable feature of this study, as larger peptides are typically considered susceptible to gastrointestinal proteolysis.

A 2001 study by Heffernan et al. published in Endocrinology examined both hGH and AOD9604 in obese mice and β3-adrenergic receptor (β3-AR) knock-out animals [6]. The study reported increased β3-AR mRNA in adipose tissue of treated animals and observed that long-term treatment with both compounds was not associated with body weight changes in β3-AR knock-out animals. The authors concluded that β3-AR-dependent pathways contribute to the lipolytic activity of hGH and AOD9604 under chronic treatment conditions, even if β3-AR is not the sole or primary mediator of the initial cellular effect [6]. The molecular basis for these interactions is discussed in the AOD9604 mechanism of action article.

A 2001 study published in the International Journal of Obesity examined both full-length hGH and a modified C-terminal fragment in obese mice and reported reductions in body weight gain, elevated plasma glycerol concentrations (an index of lipolysis), and increased in vivo fat oxidation in treated animals relative to controls [7]. A pharmacologically important observation in this study was that the C-terminal fragment — unlike full-length hGH — was not associated with hyperglycemia or reduced insulin secretion in the animal models studied, suggesting a more favorable metabolic safety profile in the preclinical setting [7].

Human Clinical Trials

Safety and tolerability across six trials. Stier, Vos, and Kenley (2013) published a consolidated analysis of six randomized, double-blind, placebo-controlled trials with AOD9604, examining safety parameters that are a known concern with full-length hGH treatment — including IGF-1 elevation, insulin resistance, and glucose intolerance [1]. The authors reported that AOD9604 displayed a safety and tolerability profile indistinguishable from placebo across all six studies. No statistically significant effects on serum IGF-1, fasting glucose, insulin, HbA1c, cortisol, or thyroid hormone levels were observed at any dose tested, and no serious adverse events attributable to AOD9604 were reported across the clinical program [1]. This safety characterization represents a substantive dataset for a synthetic hGH-derived peptide.

Phase IIb OPTIONS study. The pivotal efficacy study enrolled 536 obese adults in a 24-week randomized, double-blind, placebo-controlled, multicenter trial. The group receiving the lowest oral dose demonstrated numerically greater weight loss compared to placebo at the 12-week mark (approximately 2.8 kg vs. 0.8 kg for placebo); the pre-specified primary endpoint for statistically significant weight reduction across the full dose range and 24-week duration was not met [1,8]. No serious adverse events attributable to AOD9604 were reported in this study, and the safety profile remained consistent with placebo across all dose arms [1]. The OPTIONS study data contributed to the body of evidence subsequently used to support the GRAS determination.

Nonclinical Safety and Metabolism Studies

Moré and Kenley (2014) published a consolidated nonclinical safety evaluation of AOD9604 in the Journal of Endocrinology and Metabolism [8]. This publication described chronic oral gavage toxicology studies in rats (six months) and cynomolgus monkeys (nine months), pharmacokinetic studies following oral and intravenous administration in pigs, and genotoxicity assessments including an Ames test, chromosomal aberration assay, and bone marrow micronucleus assay. The authors reported no evidence of genotoxic activity in any of the assays, and characterized the compound as generally safe in chronic oral application in both rodent and primate species [8]. This publication formed part of the basis for AOD9604's GRAS determination and represents the most comprehensive nonclinical characterization of the compound in the published literature.

Musculoskeletal Research

A 2015 study by Kwon, Park, and Lee published in the Annals of Clinical and Laboratory Science examined intra-articular administration of AOD9604, with and without hyaluronic acid, in a collagenase-induced knee osteoarthritis rabbit model [9]. The authors reported that animals in the combined AOD9604 and hyaluronic acid group exhibited lower histopathological and morphological scores compared with control groups, describing cartilage tissue characteristics consistent with the study's regenerative endpoints [9]. This study extended AOD9604 research beyond its original metabolic focus, suggesting that the compound's biological activity may not be confined to adipose tissue and lipid metabolism. No human clinical trials of AOD9604 in osteoarthritis or musculoskeletal indications have been identified in the peer-reviewed literature to date, representing a frontier for future translational investigation.

Areas of Ongoing Investigation

Several questions in the AOD9604 literature remain open and constitute productive areas for future research:

Primary receptor identification. The receptor through which AOD9604 initially engages adipose tissue cells has not been definitively identified. The β3-AR data from Heffernan et al. (2001) characterizes β3-AR as a downstream component rather than a primary mediator [6], positioning primary receptor identification as one of the more tractable unresolved questions in the mechanistic literature.

Mechanism of oral bioavailability. The peptide's activity following oral administration in rodent models raises questions about gastrointestinal stability and transport that have not been fully resolved in the published pharmacokinetic literature — questions with broader relevance to oral peptide delivery research.

Musculoskeletal mechanism. The reported cartilage-related findings in the 2015 rabbit model study [9] have not been mechanistically characterized in follow-up publications. This represents an emerging area of investigation that may expand understanding of the biological targets accessible to hGH C-terminal fragments.

Translational research opportunities. The preclinical mechanistic dataset for AOD9604 is one of the more detailed in the hGH fragment literature. The safety profile established across six human trials provides a foundation from which future mechanistic and translational studies could proceed. Researchers comparing GH-axis peptides across the secretagogue cluster may also consult the tesamorelin published research, which covers human clinical trial data for a GHRH analogue operating through a distinct upstream mechanism. Research-grade AOD9604 from SpartaLabs is batch-tested by independent third-party laboratories for HPLC purity and mass spectrometric identity confirmation.

References

1. Stier H, Vos E, Kenley D. Safety and tolerability of the hexadecapeptide AOD9604 in humans. Journal of Endocrinology and Metabolism. 2013;3(1–2):7–15. https://www.jofem.org/index.php/jofem/article/view/157

2. Wu Z, Ng FM. Antilipogenic action of synthetic C-terminal sequence 177-191 of human growth hormone. Biochemistry and Molecular Biology International. 1993;30(1):187–196. PMID: 8358331.

3. Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R. Molecular and cellular actions of a structural domain of human growth hormone (AOD9401) on lipid metabolism in Zucker fatty rats. Journal of Molecular Endocrinology. 2000;25(3):287–298. PMID: 11116208.

4. Natera SH, Jiang WJ, Ng FM. Reduction of cumulative body weight gain and adipose tissue mass in obese mice: response to chronic treatment with synthetic hGH 177-191 peptide. Biochemistry and Molecular Biology International. 1994;33(5):1011–1021. PMID: 7987248.

5. Heffernan MA, Jiang WJ, Thorburn AW, Ng FM. Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism. American Journal of Physiology – Endocrinology and Metabolism. 2000;279(3):E501–E507. https://doi.org/10.1152/ajpendo.2000.279.3.E501

6. Heffernan MA, Summers RJ, Thorburn A, Ogru E, Gianello R, Jiang WJ, Ng FM. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and β3-AR knock-out mice. Endocrinology. 2001;142(12):5182–5189. https://doi.org/10.1210/endo.142.12.8522

7. Heffernan M, Thorburn AW, Fam B, Summers R, Conway-Campbell B, Waters MJ, Ng FM. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. International Journal of Obesity. 2001;25(10):1442–1449. PMID: 11673763.

8. Moré MI, Kenley D. Safety and metabolism of AOD9604, a novel nutraceutical ingredient for improved metabolic health. Journal of Endocrinology and Metabolism. 2014;4(3):116–126. https://jofem.org/index.php/jofem/article/view/213

9. Kwon DR, Park GY, Lee SC. Effect of intra-articular injection of AOD9604 with or without hyaluronic acid in rabbit osteoarthritis model. Annals of Clinical and Laboratory Science. 2015;45(4):426–432. PMID: 26275694.